FIVE THINGS TO KNOW ABOUT ...

Acute primary HIV infection

Michael L. Rekart MD, Josephine MacIntosh PhD

Although most patients with acute HIV infection are symptomatic, the diagnosis is often missed

In a descriptive cohort study, 41 of 46 people with acute HIV infection sought medical attention for related symptoms.¹ Seventy per cent reported experiencing such symptoms as fever, fatigue, sore throat and weight loss for a median of 14 days. Only 25% received a correct diagnosis.

Routine HIV testing will miss most acute infections

The usual HIV screening tests — third- and fourth-generation enzyme immunoassays — begin to identify infection within 22 days after exposure.⁵ However, patients are often advised to wait 12 weeks after risky behaviour before testing.⁵ This will result in missed opportunities to diagnose acute HIV infection.

HIV infection can often be detected within 22 days after exposure

Third-generation enzyme immunoassays start to detect anti-HIV antibodies within 20–22 days after exposure; fourth-generation enzyme immunoassays, which test for p24 antigen and anti-HIV antibodies, can yield positive results within 16–18 days.⁵ RNA nucleic acid amplification testing starts to detect HIV infection within 7–14 days. At \$75 per test, these RNA tests are too costly for routine use and are typically reserved to detect pre-seroconversion infection in at-risk prenatal women and to rule out neonatal infection.

Risk of transmission may be greatest within three months after infection

Well-designed studies have shown very high HIV viral loads in blood, semen and vaginal secretions during the first two to three months after infection (Figure 1).² Research suggests that up to 49% of transmission events could be ascribed to recently infected index subjects.⁴

Most patients who know they have acute HIV infection will change their behaviour

In one study, 76% of 98 high-risk homosexual men with acute HIV infection eliminated the risk of forward HIV transmission for 12 weeks after diagnosis.⁶ Early diagnosis also allows for timely initiation of treatment.

For references, see Appendix 1 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.101605/-/DC1).

Competing interests: None declared.

This article has been peer reviewed.

Affiliations: From the BC Centre for Disease Control (Rekart), Vancouver, BC; the University of British Columbia (Rekart, MacIntosh), Vancouver, BC; and the University of Victoria (MacIntosh), Victoria, BC

Correspondence to: Dr. Michael L. Rekart, michael.rekart@bccdc.ca

CMAJ 2011. DOI:10.1503/cmaj.101605